Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 10 - 26 tags : Study save search
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
Published: 2022-10-26 (Crawled : 22:00) - biospace.com/
ALPN | $64.42 -0.02% 3.1M
|
Health Technology
|
| O: 1.4%
H: 5.7%
C: -1.73%
alpn-303 sciences study phase 1
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-26 (Crawled : 14:00) - biospace.com/
EPIX | $6.755 0.52% 35K
|
Health Technology
|
| O: 19.19%
H: 148.78%
C: 135.12%
epi-7386 candidate results cancer study prostate cancer phase 1
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Published: 2022-10-26 (Crawled : 14:00) - globenewswire.com
GTHX | $4.01 -3.84% 310K
|
Health Technology
|
| O: -0.62%
H: 5.64%
C: -0.81%
lung trilaciclib therapeutics cancer study initiated
Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide
Published: 2022-10-26 (Crawled : 13:20) - biospace.com/
SWKH | $17.41 0.4% 710
|
Miscellaneous
|
| O: -0.22%
H: 1.59%
C: 0.82%
ovarest biopharma study
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2022-10-26 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | $0.1657 -6.44% 21M
|
Health Technology
|
| O: -0.35%
H: 2.85%
C: 2.56%
treatment research diarrhea breast health crofelemer cancer publication study
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
CADL | $5.395 -1.19% 250K
|
|
| O: 7.69%
H: 0.0%
C: -9.52%
immunotherapy car-t therapeutics therapy study
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
QSAM | $7.78 12K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -7.72%
cyclosam treatment bone trial cancer study
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
Published: 2022-10-26 (Crawled : 12:20) - globenewswire.com
COCP | $1.495 5.2K
|
Health Technology
|
| O: -0.93%
H: 7.0%
C: 1.88%
cc-4234 candidate antiviral influenza study cc-42344 phase 1
Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
VRAX | $0.661 -2.75% 5.9K
|
n/a
|
| O: 1.33%
H: 0.0%
C: -3.95%
covid-19 study group
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - nutriband.com
NTRB | $4.04 18K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.024 57K
|
Health Technology
|
| O: -3.14%
H: 10.39%
C: 3.25%
conference therapeutics study phase 2b
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
ATHE | $2.05 -4.21% 41K
|
Health Technology
|
| O: 1.64%
H: 2.2%
C: -4.42%
meeting neurological therapeutics presentation study
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. with Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
NTRB | $4.04 18K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.024 57K
|
Health Technology
|
| O: -3.14%
H: 10.39%
C: 3.25%
conference therapeutics study phase 2b
TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair
Published: 2022-10-26 (Crawled : 11:00) - globenewswire.com
TELA | $4.78 -7.18% 52K
|
Health Technology
|
| O: 0.23%
H: 4.1%
C: 1.69%
ovitex matrix results publication study benefits
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
Published: 2022-10-26 (Crawled : 11:00) - biospace.com/
ALRN | $4.82 -3.6% 69K
|
Health Technology
|
| O: 1.05%
H: 1.56%
C: -6.81%
alrn-6924 conference bone therapeutics results international study
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
Published: 2022-10-26 (Crawled : 11:00) - globenewswire.com
NRIX 2 d | $13.4 -7.2% 340K
|
Health Technology
|
| O: 2.5%
H: 3.66%
C: -1.95%
nx-2127 therapeutics response study
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
Published: 2022-10-26 (Crawled : 08:00) - biospace.com/
ATRA | $0.6782 -1.95% 880K
|
Health Technology
|
| O: -0.21%
H: 5.77%
C: 1.07%
ata188 extension sclerosis study phase 1
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.